RBC Capital maintains Revvity at Sector Perform, raises price target to $172 from $135
RBC Capital kept its Sector Perform rating on Revvity but raised its price target to $172 from $135, a 27.4% increase. This implies a 5.2% upside from the Nov 3 close of $163.48. Recent analyst price targets for Revvity range from $160 to $180.
How this was made
The 30-second read
Why it matters
Analyst upgrades often trigger short‑term buying, but the effect may be muted if broader market sentiment is neutral.
Market read
A notable analyst upgrade that could provide a short‑term catalyst for Revvity shares.
What to watch
Potential headwinds from supply‑chain constraints and competitive pricing pressure.
Background
RBC Capital regularly updates price targets; this is the latest adjustment for Revvity.
Ticker impact
RBC Capital raised its price target on Revvity to $172 from $135, indicating a new bullish outlook.
likely upward pressure as investors price in the higher target.
Analyst target hikes typically lead to buying interest, especially when the increase is sizable (27%).
Market effects
The target raise may lift sentiment in the life‑sciences equipment sector.
U.S. biotech and medical‑device markets could see modest gains.
Limited to investors tracking Revvity and related peers.
Counterpoint
The target increase could be premature if Revvity's upcoming earnings miss expectations.
Key entities
- companyRevvity Inc.
U.S. life‑sciences and diagnostics equipment manufacturer.
- analystRBC Capital Markets
Equity research firm that issued the new price target.
